The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Francesco Boccardo

IRCCS San Martino University Hospital - IST National Cancer Research Institute and the University of Genoa

Academic Unit of Medical Oncology (UOC Oncologia Medica B)

Largo Rosanna Benzi 10

16132 Genoa

Italy

[email]@unige.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • IRCCS San Martino University Hospital - IST National Cancer Research Institute and the University of Genoa, Academic Unit of Medical Oncology (UOC Oncologia Medica B), Largo Rosanna Benzi 10, 16132 Genoa, Italy. 2013
  • The National Cancer Research Institute and the University of Genoa, Genoa, Italy. 2005 - 2008
  • Department of Oncology, Biology and Genetics, University of Genoa, Genoa, Italy. 2008
  • University of Genoa, Italy. 2005 - 2006
  • National Cancer Research Institute, 16132 Genoa, Italy. 2005

References

  1. Dihydrotestosterone and bicalutamide do not affect periostin expression in androgen-dependent LNCaP prostate cancer cell lines. Argellati, F., Nuzzo, P.V., Ricci, F., Mangerini, R., Rubagotti, A., Boccardo, F. Anticancer Res. (2013) [Pubmed]
  2. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Boccardo, F., Rubagotti, A., Conti, G., Battaglia, M., Cruciani, G., Manganelli, A., Ricci, S., Lapini, A. Oncology (2008) [Pubmed]
  3. Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer. Boccardo, F. Nat. Clin. Pract. Oncol (2008) [Pubmed]
  4. Switching to aromatase inhibitors in early breast cancer. Boccardo, F., Rubagotti, A. Lancet (2007) [Pubmed]
  5. Enterolactone as a risk factor for breast cancer: a review of the published evidence. Boccardo, F., Puntoni, M., Guglielmini, P., Rubagotti, A. Clin. Chim. Acta (2006) [Pubmed]
  6. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Boccardo, F., Rubagotti, A., Guglielmini, P., Fini, A., Paladini, G., Mesiti, M., Rinaldini, M., Scali, S., Porpiglia, M., Benedetto, C., Restuccia, N., Buzzi, F., Franchi, R., Massidda, B., Distante, V., Amadori, D., Sismondi, P. Ann. Oncol. (2006) [Pubmed]
  7. Adjuvant chemotherapy of bladder cancer. Boccardo, F., Palmeri, L. Ann. Oncol. (2006) [Pubmed]
  8. Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. Boccardo, F., Rubagotti, A., Battaglia, M., Zattoni, F., Bertaccini, A., Romagnoli, A., Conti, G. Int. J. Biol. Markers (2006) [Pubmed]
  9. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. Boccardo, F., Rubagotti, A., Battaglia, M., Di Tonno, P., Selvaggi, F.P., Conti, G., Comeri, G., Bertaccini, A., Martorana, G., Galassi, P., Zattoni, F., Macchiarella, A., Siragusa, A., Muscas, G., Durand, F., Potenzoni, D., Manganelli, A., Ferraris, V., Montefiore, F. J. Clin. Oncol. (2005) [Pubmed]
  10. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Boccardo, F., Rubagotti, A., Puntoni, M., Guglielmini, P., Amoroso, D., Fini, A., Paladini, G., Mesiti, M., Romeo, D., Rinaldini, M., Scali, S., Porpiglia, M., Benedetto, C., Restuccia, N., Buzzi, F., Franchi, R., Massidda, B., Distante, V., Amadori, D., Sismondi, P. J. Clin. Oncol. (2005) [Pubmed]
  11. 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitro. Boccardo, F., Medicina, D., Galmozzi, F., Emionite, L., Lo Casto, M. Anticancer Res. (2005) [Pubmed]
 
WikiGenes - Universities